C2 Therapeutics, a privately held company founded to address the limitations of current Barrett’s Esophagus (BE) treatment options, today announced that it enrolled the 15th patient in its Cryoballoon Focal Ablation System international study. Additionally, 10 patients have reached the 2-month follow-up period.
Initial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation
The abstract, Initial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation (1299398) will be presented during the 53rd Annual Meeting of The Society for Surgery of the Ailmentary Tract (SSAT) in conjunction with DDW at the San Diego Convention Center in San Diego, California.
The abstract can be viewed here: http://meetings.ssat.com/abstracts/2012/QS17.cgi
Redwood City-based C2Therapeutics is hoping to kill diseased tissue in people’s esophaguses before it becomes one of the most deadly cancers of the human body. For the 40 million Americans with acid reflux disease, treatment is often over the counter medication or a simple change in diet. However, one in five with acid reflux will likely develop Barrett’s Esophagus, a pre-cancerous condition that makes patients 30 to 125 times more likely to develop cancer of the esophagus. See Complete Story.
The CryoBalloon device enables circumferential mucosal ablation in a 1-step process by using a novel, through-the-scope balloon. The maximal effect on the mucosa is achieved with a 12-second application time. Because of its ease of use, this new device merits further study so that we can find its possible role in the treatment of Barrett’s esophagus.